Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
about
Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewA randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodesThe present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesDynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.Evolutionary diversification of SPANX-N sperm protein gene structure and expressionImplications of Lymphatic Transport to Lymph Nodes in Immunity and ImmunotherapyLUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancerSynthetic peptides as cancer vaccines.Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.Towards patient-specific tumor antigen selection for vaccination.Antigen-specific immunotherapy and cancer vaccines.Clinical application of dendritic cells in cancer vaccination therapy.Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cellsDNA fusion gene vaccines against cancer: from the laboratory to the clinic.Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.The role of debulking surgery in metastatic melanoma.Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.Induction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine.Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
P2860
Q28084805-051849EE-33A5-4C06-96EF-BF039338675BQ30278070-E30ADDD5-27EB-4C12-9412-1DF0004297BFQ30409722-45D7E6B1-F6EE-4C5C-BC82-82CD633BF44EQ30411269-589A3F62-7E25-4469-882A-8CE11C1AF296Q30425111-8089813D-DC64-4B24-B541-13709400FFDEQ30430002-CF0B1650-88CC-4EAA-801E-FC0F70B7D37CQ30433911-9698124B-DF17-46E8-B79E-141A879873C7Q30434822-3C6F2B0E-108F-44A0-A39F-63E572C18CDEQ30436792-73858A2A-44FE-4A0C-9FDD-8FB23E96634CQ30438159-3792C064-C039-4E3F-8DC1-3A49DAEE4E30Q30444065-F371B974-5628-43DB-AC47-0817344F7037Q30445102-E95A1D37-2009-4A9B-94B8-91A0AF31CB36Q33920298-D3265260-5A2E-47F8-AAD0-D2578EFC6639Q34111719-9DB58B21-A4C9-4B8C-A6A2-8FF3327312C1Q34669820-18A3C9D7-D696-418D-86E8-BA3468A2632DQ34775850-A9F7A75A-D370-4651-9B6B-DB63504AB504Q34972916-8EBC7442-5262-40C6-A7D0-25DDE9E3CE40Q35005912-3C1B823D-84A3-4CCA-80FF-DC046F77EFACQ35005960-20577657-D8BD-4632-B103-EF106B60A791Q35199473-940B539D-D509-4599-9AB3-A238A6369725Q35219339-97781D7A-A5F1-4668-A0C7-9E658531AB35Q35747474-254D7F84-CD61-43C5-B058-1456DABAC971Q35826392-189FAB3D-987A-49F4-89F1-E49BC29C5333Q36353361-37332BE9-BA8C-48EC-BE02-D3BB460BDDA2Q36745336-4CF89941-6C8B-4E10-9A68-FB65712FB613Q37382380-34CE80FE-0A8D-486D-8638-6EF07F52A059Q37582966-1FE43F09-1D27-4E9D-AC1B-746BAFBC73A1Q38372054-5EC0DACA-7F81-483A-93E2-58656E04668AQ40238006-751CDBBB-AB30-45BF-86B7-F018A5B814B8Q40285760-A26D9760-4321-4B12-9600-FF0BD1A5A5DFQ45073466-E44135EB-30C8-459E-94AF-ED48D2C98852Q45871757-4646154F-9F04-42D1-B196-AA5320EEBB8AQ51060418-0CC4343E-D16C-4949-98F7-9CA4AF12964BQ54211947-8F69941A-E4AF-4151-B5EB-DE7FDD3DCE74
P2860
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@ast
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@en
type
label
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@ast
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@en
prefLabel
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@ast
Evaluation of peptide vaccine ...... al blood of melanoma patients.
@en
P2093
P1476
Evaluation of peptide vaccine ...... ral blood of melanoma patients
@en
P2093
C L Slingluff
D H Deacon
G V Yamshchikov
H Galavotti
J W Patterson
P304
P356
10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5
P577
2001-06-01T00:00:00Z